Sign in
Active, not recruitingPhase 3

Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial

Key facts

Who runs it
Bayside Health
Where
Australia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
826 people, planned
Started
1 Nov 2022
Ended
31 Aug 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tranexamic Acid 100Mg/ml Inj Vial 10ml
  • Placebo
Record updated
31 December 2025

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Adult patients scheduled for elective gastrointestinal (oesophageal, gastric, hepatobiliary, colorectal) surgery
  • with 2 or more risk factors for complications:
  • age ≥70 years,
  • American Society of Anesthesiologists (ASA) physical status 3 or 4,
  • heart failure, diabetes,
  • chronic respiratory disease,
  • obesity (BMI ≥30 kg/m2),
  • vascular disease,
  • preoperative haemoglobin <100 g/L,
  • renal impairment (se. creatinine ≥150 micromol/L), or low albumin (<30 g/L)
  • Written informed consent will be obtained. Exclusion criteria
  • Poor spoken and/or written language comprehension,
  • laparoscopic and other minor (eg. closure of stoma) surgery,
  • pre-existing infection/sepsis,
  • history of spontaneous pulmonary embolism or arterial thrombosis,
  • current arterial or venous thrombosis,
  • familial thrombophilia (e.g. Lupus anticoagulant, protein C deficiency, factor V Leiden),
  • contraindication to TxA

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Prophylactic TxA administration in patients undergoing major gastrointestinal surgery reduces the incidence of delirium after surgery when compared with placebo. The unifying hypothesis is that systemic and neuro-inflammation lead to neuronal injury and resultant postoperative delirium.

The 2 groups in the trial

  • Tranexamic AcidExisting treatment, for comparison

    12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.

    Treatment: Tranexamic Acid 100Mg/ml Inj Vial 10ml

  • PlaceboPlacebo, for comparison

    12 mg/kg, before surgical incision, and then an infusion of 3 mg/kg/h until the end of surgery.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial (a Substudy of the TRIGS Trial)
Record updated
31 December 2025